ACAD
29.27
+1.05
+3.72%
AEMD
2.3
+0.25
+12.20%
APRI
1.01
-0.02
-1.94%
ARNA
16.6
+0.85
+5.40%
ATEC
1.86
+0.05
+2.76%
CNAT
5.11
+0.19
+3.86%
CRXM
0.175
+0.013
+7.9827%
CYTX
1.01
-0.02
-1.94%
DXCM
78.33
+0.49
+0.63%
GNMK
12.39
+0.18
+1.47%
HALO
14.59
+0.27
+1.89%
ILMN
177.38
+2.08
+1.19%
INNV
0.11
0.00
+4.27%
INO
8.06
+0.09
+1.13%
ISCO
1.15
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
120.2
+4.49
+3.88%
LPTN
2.93
0.00
0.00%
MBVX
1.42
-0.03
-2.0621%
MEIP
2.13
+0.04
+1.91%
MNOV
5.47
+0.08
+1.48%
MRTX
3.85
+0.3
+8.45%
MSTX
0.131
0.00
0.00%
NBIX
47.47
+1.8
+3.94%
NUVA
76.83
-0.72
-0.93%
ONCS
1.16
+0.07
+6.42%
ONVO
2.67
+0.01
+0.38%
OREX
2.99
+0.02
+0.67%
OTIC
17.5
+1.45
+9.03%
QDEL
25.98
+0.17
+0.66%
RCPT
231.96
0.00
0.00%
RGLS
0.949
+0.004
+0.4232%
RMD
78.39
-0.08
-0.10%
SCIE
0
0.00
0.00%
SPHS
2.05
+0.01
+0.49%
SRNE
1.9
+0.15
+8.57%
TROV
0.946
+0.047
+5.2374%
VICL
2.47
+0.05
+2.07%
VOLC
18
0.00
0.00%
ZGNX
15
+0.25
+1.69%
ACAD
29.27
+1.05
+3.72%
AEMD
2.3
+0.25
+12.20%
APRI
1.01
-0.02
-1.94%
ARNA
16.6
+0.85
+5.40%
ATEC
1.86
+0.05
+2.76%
CNAT
5.11
+0.19
+3.86%
CRXM
0.175
+0.013
+7.9827%
CYTX
1.01
-0.02
-1.94%
DXCM
78.33
+0.49
+0.63%
GNMK
12.39
+0.18
+1.47%
HALO
14.59
+0.27
+1.89%
ILMN
177.38
+2.08
+1.19%
INNV
0.11
0.00
+4.27%
INO
8.06
+0.09
+1.13%
ISCO
1.15
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
120.2
+4.49
+3.88%
LPTN
2.93
0.00
0.00%
MBVX
1.42
-0.03
-2.0621%
MEIP
2.13
+0.04
+1.91%
MNOV
5.47
+0.08
+1.48%
MRTX
3.85
+0.3
+8.45%
MSTX
0.131
0.00
0.00%
NBIX
47.47
+1.8
+3.94%
NUVA
76.83
-0.72
-0.93%
ONCS
1.16
+0.07
+6.42%
ONVO
2.67
+0.01
+0.38%
OREX
2.99
+0.02
+0.67%
OTIC
17.5
+1.45
+9.03%
QDEL
25.98
+0.17
+0.66%
RCPT
231.96
0.00
0.00%
RGLS
0.949
+0.004
+0.4232%
RMD
78.39
-0.08
-0.10%
SCIE
0
0.00
0.00%
SPHS
2.05
+0.01
+0.49%
SRNE
1.9
+0.15
+8.57%
TROV
0.946
+0.047
+5.2374%
VICL
2.47
+0.05
+2.07%
VOLC
18
0.00
0.00%
ZGNX
15
+0.25
+1.69%
Home » Archive by Category

Syndication

Purchasing Agent

June 16, 2017 – 11:18 am

BioLegend develops world-class, cutting-edge antibodies and reagents for biomedical research, manufactured in our state-of-the-art facility in San Diego, CA. Our mission is to accelerate research and discovery by providing the highest quality product […

BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis 2017 Congress

June 16, 2017 – 4:31 am

Oral Presentation to Include Interim Results from its Ongoing Phase 1/2 BMN 270 Clinical Program, a Gene Therapy for Hemophilia AConference call and web-cast to be held July 11th at 2:30pm CEST/8:30am ET

SAN RAFAEL, Calif., June 16, 2017 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in a late breaking abstract session at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress being held July 8-13, 2017 in Berlin, Germany. The presentation will report interim results from a Phase 1/2 study of BMN 270, an AAV5-FVIII Gene transfer in severe hemophilia.

“We feel privileged to be presenting the only human data in gene therapy for hemophilia A at ISTH,” said Hank Fuchs, M.D., President Worldwide Research and Development at BioMarin. “We are committed to further our ongoing clinical program with BMN 270, which has the potential to change the course of hemophilia A treatment, the most common form of the disease, and look forward to sharing our latest findings.”

ISTH is a global not-for-profit membership organization advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders. The congress hosts the world’s leading experts on thrombosis, hemostasis and vascular biology, presenting the most recent advances to improve patient care.

Oral Presentation – Late Breaking Abstract Session

Title

Authors

Interim Results from a Phase 1/2 AAV5-FVIII
Gene Transfer in Patients with Severe

Hemophilia A

 

Presentation: July 11 at 9:30-9:38 AM CEST

J. Pasi, S. Rangarajan, L. Walsh, W.
Lester, D. Perry, B. Madan, H. Yu, G.F.
Pierce, W.Y. Wong

Conference Call to be held Tuesday, July 11th at 2:30pm CEST/8:30am ET 

Interested parties may access a live webcast of the conference call via the investor section of the BioMarin website, www.biomarin.com. The Late Breaker slide presentation will be available to download in advance of the call.  A replay of the call will be archived on the site for one week following the call.

U.S. / Canada Dial-in Number: (866) 502-9859
International Dial-in Number: (574) 990-1362
Conference ID: 41581309

Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 41581309

About Hemophilia A

Hemophilia A is a genetic disease caused by the deficiency of clotting factor VIII. It is the most common type of hemophilia and occurs much more frequently in males; incidence is estimated at 1 in 4,000-5,000 male births. People born with hemophilia produce little or no clotting factors. The two main types of hemophilia are A and B. People with hemophilia A are missing or have low levels of clotting factor VIII.

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The Company’s portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BioMarin.com.

Forward Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: our research on hemophilia A treatment and our potential to change the course of hemophilia A treatment. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: results and timing of current and planned preclinical studies and clinical trials of BMN 270, including final analysis of the Phase 1/2 data; any potential adverse events observed in the continuing monitoring of the patients in the Phase 1/2 trial; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities; a potential decision by the EMA to remove BMN 270 from the PRIME scheme or the accelerated assessment framework; the content and timing of decisions by local and central ethics committees regarding the clinical trials; our ability to successfully manufacture the product candidate for the preclinical and clinical trials; and those factors detailed in BioMarin’s filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption “Risk Factors” in BioMarin’s 2016 Annual Report on Form 10-K, and the factors contained in BioMarin’s reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin® is a registered trademark of BioMarin Pharmaceutical Inc.

Contact:

Investors:

Media:

Traci McCarty

Debra Charlesworth

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558

(415) 455-7451

 

SOURCE BioMarin Pharmaceutical Inc.

Bio Roundup: Trumpcare Is Mean, SCOTUS Says Go, Merck’s Myeloma No

June 15, 2017 – 11:00 pm

What exactly does the American Health Care Act, the Republican proposal to replace Obamacare, currently look like? Few people know, because the Senate version is being negotiated behind closed doors…

[[Click headline to continue reading.]]

Experienced Biotech Patent Prosecution Agent – Junior to Senior (SD) – Morrison & Foerster – San Diego, CA

June 15, 2017 – 10:42 pm

Position: Patent Prosecution Agent – Biotech Office: San Diego Office Experience: 2 – 7 Years of Experience Ideal Candidate We have a need for a Patent…
From Morrison & Foerster – Fri, 16 Jun 2017 06:42:39 GMT – View all San Diego, CA jobs

Protein Conjugation Chemist – Biolegend – San Diego, CA

June 15, 2017 – 3:41 pm

This is a great opportunity to learn, contribute, and grow professionally in a fast paced biotechnology company committed to excellence and novel product…From Biolegend – Thu, 15 Jun 2017 23:41:14 GMT – View all San Diego, CA jobs

Purchasing Agent – Biolegend – San Diego, CA

June 15, 2017 – 3:41 pm

Prior experience in life science, biotechnology or pharmaceutical environment. BioLegend develops world-class, cutting-edge antibodies and reagents for…From Biolegend – Thu, 15 Jun 2017 23:41:11 GMT – View all San Diego, CA jobs

Purification Development Associate – Biolegend – San Diego, CA

June 15, 2017 – 3:41 pm

This is a great opportunity to enhance your knowledge in a highly competitive biotechnology industry. The Purification Development Associate is an important…From Biolegend – Thu, 15 Jun 2017 23:41:11 GMT – View all San Diego, CA jobs

Global Kinetics Corporation Big Data Highlights Unmet Needs & Global Variations in Parkinson’s Disease

June 15, 2017 – 12:30 pm

SAN FRANCISCO and MELBOURNE, Australia, June 15, 2017 /PRNewswire/ — Global Kinetics Corporation (GKC), a leader in digital health technology for people with Parkinson’s disease (PD), today announced that it has developed a dataset of more than 10,000 reports of symptoms from patients with PD. The database was used to analyze symptomology from patients across the globe and presented in a poster at the recent International Congress of Parkinson’s Disease and Movement Disorders.

The analysis of data from 10,000 de-identified Personal KinetiGraph™ (PKG™) reports, generated across four geographies including the US, Europe, Australia and Asia between January 2012 and January 2017, showed significant regional variation in PD motor symptoms, which may be due, in part, to differences in the availability of treatment options and variations in clinical practice.

In addition, the analysis highlighted that a meaningful proportion of patients in every region experienced suboptimal control of their PD symptoms, including bradykinesia, dyskinesia, fluctuations, tremor, and immobility. Uncontrolled symptomology in PD has been associated with increased healthcare costs and reduce patient quality of life.

“This exploratory study shows the power of continuous objective measurement in PD and how a rich dataset like this could be used to identify and target unmet needs and thereby enhance healthcare benchmarking in the disease,” said Peter Lynch, Head of Global Market Access, Reimbursement and Health Economics for GKC and the presenting author of the study. “Up until now, we believe that a collection of truly objective Parkinson’s patient symptoms like this has not existed, and we believe it may offer a rich resource for researchers to understand the disease more deeply.”

Use of continuous objective measurement in routine clinical care of PD enables the identification and quantification of motor symptoms and allows clinicians to assess and track patient’s symptoms over time.

Treating PD presents challenges as patients’ symptoms can fluctuate from day to day and even throughout the course of a day. People with PD rely heavily on their own interpretation of their symptoms, as well as evaluation from their doctors to understand how their disease is progressing and act to optimize their medication regimens. The PKG provides an objective measure of patients’ symptoms, allowing physicians to objectively assess symptoms and help make decisions about when to alter treatment.

“Even though literature suggests that more than 75 percent of PD patients develop motor fluctuations, no one knows how large the need for dose adjustments or advanced treatments really is,” said Filip Bergquist, associate professor in the department of neurology at Sahlgrenska University Hospital in Sweden and a co-author on the poster. “This descriptive study indicates that there is substantial room for improvement, and it should be followed by population based studies as well as evaluations of whether the availability of objective measurements will improve outcomes.”

About Global Kinetics Corporation
Global Kinetics is a commercial-stage digital health company revolutionizing the management of Parkinson’s disease by providing the first continuous and objective measurement of patients’ symptoms in everyday environments. The company’s Personal KinetiGraph™ (PKG™) is a patient-friendly, algorithm-based system that records body movements and other symptoms over the course of many days and creates data-driven reports that empower more personalized treatment and management decisions—with the goal of leading to a higher quality of life for patients. Global Kinetics continues to pursue partnerships with major pharmaceutical and medical technology companies to help measure the efficacy of new and advanced therapies for the world’s most widespread movement disorder.

For more information, visit: www.globalkineticscorporation.com

 

SOURCE Global Kinetics Corporation

Quality Assurance Associate – CV Sciences – San Diego, CA

June 15, 2017 – 11:51 am

Document Control under Quality supervision (revise procedures, issue production batch records, provide line clearance, revise batch records as needed, update…From Indeed – Thu, 15 Jun 2017 19:51:10 GMT – View all San Diego, CA jobs

Quality Assurance Specialist – CV Sciences – San Diego, CA

June 15, 2017 – 11:51 am

Document Control under Quality supervision (revise procedures, issue production batch records, provide line clearance, revise batch records as needed, update…From Indeed – Thu, 15 Jun 2017 19:51:10 GMT – View all San Diego, CA jobs